Gene Therapy Market - Global Forecast to 2032
商品番号 : SMB-18735
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年2月 |
| ページ数 | 434 |
| 図表数 | 720 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global gene therapy market is projected to reach USD 36.55 billion by 2032 from USD 8.85 billion in 2024, at a CAGR of 19.4% during the forecast period of 2024 to 2032.
世界の遺伝子治療市場は、2024年から2032年の予測期間中にCAGR 19.4%で、2024年の88億5,000万米ドルから2032年までに365億5,000万米ドルに達すると予測されています。
The growth of the gene therapy market has been significantly driven by increasing R&D investment by key players for the development gene therapy drugs and growing approval of novel gene therapies. However, complex regulatory frameworks and ethical concerns regarding genetic modifications are restraining market growth.
遺伝子治療市場の成長は、遺伝子治療薬開発の主要企業による研究開発投資の増加と新しい遺伝子治療の承認の増加によって大きく推進されてきました。しかし、複雑な規制の枠組みと遺伝子組み換えに関する倫理的懸念が市場の成長を抑制しています。
“The intravenous route segment accounted for the largest share by route of administration in 2023.”
Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.
“The US has continued to dominate the gene therapy market during the forecast period of 2024-2032.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals’ importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of key Companies Profiled in the Report:
Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Ferring B.V. (Switzerland), Pfizer Inc. (US), Amgen, Inc. (US), Johnson & Johnson Services, Inc. (US), Daiichi Sankyo Company, Limited. (Japan), BioMarin Pharmaceutical Inc. (US), Kyowa Kirin Co., Ltd. (Japan), Nippon Shinyaku Co., Ltd. (Japan), PTC Therapeutics (US), UniQure NV (Netherlands), Juventas Cell Therapy Ltd. (China), CRISPR Therapeutics (Switzerland), bluebird bio, Inc. (US), Krystal Biotech, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), JW (Cayman) Therapeutics Co. Ltd (China), IASO Biotechnology (China), CARsgen Therapeutics Holdings Limited (China), Adaptimmune (UK), Sibiono GeneTech Co. Ltd. (China), and Ultragenyx Pharmaceutical Inc. (US).
Research Coverage:
This research report categorizes the gene therapy market by Therapy Type (Gene Silencing Therapy, Cell Replacement Therapy, Gene Augmentation Therapy and Other Therapies)), by Vector (Viral Vectors (Retroviral Vector (Gamma retroviral vectors, Lentiviral Vectors) AAV Vectors, and Other Viral Vectors), Non-viral Vectors (Oligonucleotides and Other Non-viral Vectors)), by Gene Type (Deficiency, Receptors, Antigen, Cytokine, Tumor Suppressor, and Othe Genes), by Therapeutic Area (Neurology, Oncology, Hematology and Other Therapeutic Areas), by Delivery Method (In Vivo and Ex Vivo), by Route of Administration (Intravenous Route, Subcutaneous Route, and Other Routes), by End User (Hospitals, Specialty Centers, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, Increasing investments in gene therapy research, Growing technological advancements, and Robust clinical trial pipeline for gene therapy), restraints (High cost of gene therapy products, Complex regulatory frameworks and ethical concerns regarding genetic modifications, and Limited manufacturing scalability), opportunities (Expansion into rare diseases and unmet needs, Increasing focus on precision medicine, and Advancements in gene therapy delivery technologies), and Challenges (Complex manufacturing process, Short shelf life and supply chain challenges, and Lack of reimbursement).
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the gene therapy market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene therapy market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the gene therapy market.
Table of Contents
1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 42
1.3.2 INCLUSIONS & EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 44
1.4 STAKEHOLDERS 44
1.5 SUMMARY OF CHANGES 45
2 RESEARCH METHODOLOGY 46
2.1 RESEARCH DATA 46
2.1.1 SECONDARY RESEARCH 47
2.1.1.1 Key data from secondary sources 48
2.1.2 PRIMARY RESEARCH 48
2.1.2.1 Insights of primary experts 50
2.2 MARKET SIZE ESTIMATION 51
2.2.1 GLOBAL MARKET ESTIMATION 51
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION 53
2.3 MARKET GROWTH RATE PROJECTIONS 54
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 56
2.5 RESEARCH ASSUMPTIONS 57
2.6 RESEARCH LIMITATIONS 58
2.7 RISK ANALYSIS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 64
4.1 GENE THERAPY MARKET OVERVIEW 64
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE & COUNTRY (2024) 65
4.3 GENE THERAPY MARKET SHARE, BY END USER, 2024 VS 2032 66
4.4 GENE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
5.2.1 DRIVERS 68
5.2.1.1 Growing demand for curative therapies for genetic disorders, rare diseases, and cancers 68
5.2.1.2 Increasing investments in gene therapy research 70
5.2.1.3 Technological advancements 71
5.2.1.4 Robust clinical trial pipeline for gene therapy 72
5.2.2 RESTRAINTS 73
5.2.2.1 High cost of gene therapy products 73
5.2.2.2 Complex regulatory frameworks and ethical concerns regarding genetic modifications 73
5.2.2.3 Limited manufacturing scalability 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 Expansion into rare diseases and unmet needs 74
5.2.3.2 Increasing focus on precision medicine 75
5.2.3.3 Advancements in gene therapy delivery technologies 76
5.2.4 CHALLENGES 76
5.2.4.1 Complex commercial manufacturing and scaling process 76
5.2.4.2 Short shelf life and supply chain challenges 77
5.2.4.3 Lack of reimbursement 77
5.3 TECHNOLOGY ANALYSIS 78
5.3.1 KEY TECHNOLOGIES 78
5.3.1.1 CRISPR-Cas9 78
5.3.1.2 RNA interference 78
5.3.1.3 Viral vectors 78
5.3.2 COMPLEMENTARY TECHNOLOGIES 79
5.3.2.1 Stem cell therapy 79
5.3.2.2 Omics technologies 79
5.3.3 ADJACENT TECHNOLOGIES 79
5.3.3.1 Nanoparticles 79
5.4 VALUE CHAIN ANALYSIS 80
5.5 SUPPLY CHAIN ANALYSIS 81
5.5.1 PROMINENT COMPANIES 81
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES 81
5.5.3 END USERS 81
5.5.4 INVESTORS, VENTURE CAPITALISTS, AND FUNDING BODIES 81
5.5.5 REGULATORY BODIES 81
5.6 ECOSYSTEM ANALYSIS 82
5.7 PATENT ANALYSIS 85
5.8 PIPELINE ANALYSIS 88
5.9 REGULATORY LANDSCAPE 89
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 89
5.9.2 REGULATORY FRAMEWORK 91
5.9.3 REIMBURSEMENT SCENARIO 92
5.10 PRICING ANALYSIS 94
5.10.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 94
5.10.2 AVERAGE SELLING PRICE TREND, BY REGION 96
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98
5.12 KEY CONFERENCES & EVENTS, 2025–2026 99
5.13 PORTER’S FIVE FORCES ANALYSIS 100
5.13.1 THREAT OF NEW ENTRANTS 101
5.13.2 THREAT OF SUBSTITUTES 101
5.13.3 BARGAINING POWER OF SUPPLIERS 101
5.13.4 BARGAINING POWER OF BUYERS 102
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 102
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 102
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
5.14.2 BUYING CRITERIA 104
5.15 INVESTMENT & FUNDING SCENARIO 105
5.16 IMPACT OF AI ON GENE THERAPY MARKET 106
6 GENE THERAPY MARKET, BY THERAPY TYPE 108
6.1 INTRODUCTION 109
6.2 GENE SILENCING THERAPY 109
6.2.1 FLEXIBILITY AND PRECISION OF GENE SILENCING THERAPIES TO SUPPORT GROWTH 109
6.3 CELL REPLACEMENT THERAPY 113
6.3.1 LONG-TERM EFFECT OF THERAPY TO SUPPORT GROWTH IN ADOPTION 113
6.4 GENE AUGMENTATION THERAPY 116
6.4.1 EFFECTIVENESS AGAINST MONOGENIC DISORDERS TO DRIVE MARKET 116
6.5 OTHER THERAPIES 120
7 GENE THERAPY MARKET, BY VECTOR 124
7.1 INTRODUCTION 125
7.2 VIRAL VECTORS 125
7.2.1 RETROVIRAL VECTORS 129
7.2.1.1 Advantages of retroviral vectors to support market growth 129
7.2.1.2 Gamma-retroviral vectors 132
7.2.1.2.1 Availability of gamma-retroviral vectors to support market growth 132
7.2.1.3 Lentiviral vectors 135
7.2.1.3.1 North America to dominate lentiviral vectors market 135
7.2.2 AAV VECTORS 138
7.2.2.1 Focus of clinical pipeline on adeno-associated viral vectors to drive growth 138
7.2.3 OTHER VIRAL VECTORS 141
7.3 NON-VIRAL VECTORS 144
7.3.1 OLIGONUCLEOTIDE VECTORS 148
7.3.1.1 Oligonucleotides to account for largest share of non-viral vectors market 148
7.3.2 OTHER NON-VIRAL VECTORS 151
8 GENE THERAPY MARKET, BY GENE TYPE 154
8.1 INTRODUCTION 155
8.2 DEFICIENCY 155
8.2.1 TECHNOLOGICAL ADVANCEMENT IN GENE THERAPIES TO BOOST GROWTH 155
8.3 RECEPTOR 159
8.3.1 INCREASING DEMAND FOR DEVELOPING RECEPTOR-BASED GENE THERAPY TO SUPPORT MARKET GROWTH 159
8.4 ANTIGEN 162
8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO PROPEL GROWTH 162
8.5 CYTOKINE 165
8.5.1 RISING R&D TO SUPPORT MARKET GROWTH 165
8.6 TUMOR SUPPRESSOR 169
8.6.1 RISING PREVALENCE OF CANCER TO PROPEL MARKET GROWTH 169
8.7 OTHER GENES 172
9 GENE THERAPY MARKET, BY THERAPEUTIC AREA 176
9.1 INTRODUCTION 177
9.2 NEUROLOGY 177
9.2.1 ENHANCED DELIVERY METHODS AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO BOOST MARKET GROWTH 177
9.3 ONCOLOGY 181
9.3.1 RISING BURDEN OF CANCER TO SUPPORT MARKET GROWTH 181
9.4 HEMATOLOGY 184
9.4.1 INCREASING PREVALENCE OF GENETIC BLOOD DISORDERS TO BOOST MARKET GROWTH 184
9.5 OTHER THERAPEUTIC AREAS 188
10 GENE THERAPY MARKET, BY DELIVERY METHOD 191
10.1 INTRODUCTION 192
10.2 IN VIVO DELIVERY 192
10.2.1 IN VIVO DELIVERY METHOD TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 192
10.3 EX VIVO DELIVERY 196
10.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO SUPPORT MARKET GROWTH 196
11 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION 200
11.1 INTRODUCTION 201
11.2 INTRAVENOUS ROUTE 201
11.2.1 HIGH EFFECTIVENESS AND LARGE SHARE OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH 201
11.3 SUBCUTANEOUS ROUTE 205
11.3.1 DEVELOPMENT OF IMPROVED DELIVERY DEVICES TO SUPPORT MARKET GROWTH 205
11.4 OTHER ROUTES 208
12 GENE THERAPY MARKET, BY END USER 212
12.1 INTRODUCTION 213
12.2 HOSPITALS 213
12.2.1 GROWING DEMAND FOR ADVANCED THERAPIES TO BOOST MARKET 213
12.3 SPECIALTY CENTERS 217
12.3.1 ADVANCEMENTS IN GENE THERAPY TECHNOLOGIES TO SUPPORT MARKET GROWTH 217
12.4 OTHER END USERS 220
13 GENE THERAPY MARKET, BY REGION 224
13.1 INTRODUCTION 225
13.2 NORTH AMERICA 225
13.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS 226
13.2.2 US 231
13.2.2.1 US to dominate North American market during forecast period 231
13.2.3 CANADA 236
13.2.3.1 Government support for expanding manufacturing facilities to propel market growth 236
13.3 EUROPE 239
13.3.1 EUROPE: MACROECONOMIC ANALYSIS 239
13.3.2 GERMANY 245
13.3.2.1 Growing pharmaceutical R&D and manufacturing to drive market 245
13.3.3 UK 249
13.3.3.1 Strong government support to propel market growth 249
13.3.4 FRANCE 253
13.3.4.1 Government investment in pharmaceutical industry to drive growth 253
13.3.5 ITALY 257
13.3.5.1 Initiatives for gene therapy development to drive growth 257
13.3.6 SPAIN 260
13.3.6.1 Expansion of biomanufacturing facilities to support market growth 260
13.3.7 SWITZERLAND 264
13.3.7.1 Presence of key pharmaceutical and biopharmaceutical companies to support market growth 264
13.3.8 NETHERLANDS 268
13.3.8.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth 268
13.3.9 REST OF EUROPE 271
13.4 ASIA PACIFIC 275
13.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS 275
13.4.2 CHINA 280
13.4.2.1 China to dominate Asia Pacific market during forecast period 280
13.4.3 JAPAN 284
13.4.3.1 Increasing initiatives supporting gene therapy adoption to propel market growth 284
13.4.4 INDIA 288
13.4.4.1 Favorable scenario for foreign direct investment to favor market growth 288
13.4.5 AUSTRALIA 292
13.4.5.1 Increasing demand for innovative therapies to propel market 292
13.4.6 SOUTH KOREA 296
13.4.6.1 Increased export of drugs to support market growth 296
13.4.7 THAILAND 299
13.4.7.1 Favorable government policies to propel adoption of advanced therapies 299
13.4.8 REST OF ASIA PACIFIC 303
13.5 LATIN AMERICA 307
13.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS 307
13.5.2 BRAZIL 312
13.5.2.1 Brazil to dominate LATAM market during forecast period 312
13.5.3 MEXICO 315
13.5.3.1 Rising demand for chronic disease treatment to support market growth 315
13.5.4 REST OF LATIN AMERICA 319
13.6 MIDDLE EAST 323
13.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS 323
13.6.2 GCC COUNTRIES 328
13.6.2.1 Saudi Arabia 332
13.6.2.1.1 Growing healthcare expenditure to boost market growth 332
13.6.2.2 UAE 336
13.6.2.2.1 Growing focus on genetic medicine development projects to drive market 336
13.6.2.3 Rest of GCC Countries 339
13.6.3 REST OF MIDDLE EAST 343
13.7 AFRICA 347
13.7.1 HIGH GROWTH POTENTIAL OF AFRICAN MARKETS TO ATTRACT KEY PLAYERS 347
13.7.2 AFRICA: MACROECONOMIC ANALYSIS 347
14 COMPETITIVE LANDSCAPE 352
14.1 OVERVIEW 352
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2024 352
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENE THERAPY MARKET, 2022−2024 352
14.3 REVENUE ANALYSIS, 2021–2023 353
14.4 MARKET SHARE ANALYSIS, 2023 354
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 356
14.5.1 STARS 357
14.5.2 EMERGING LEADERS 357
14.5.3 PERVASIVE PLAYERS 357
14.5.4 PARTICIPANTS 357
14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2023 359
14.5.5.1 Company footprint 359
14.5.5.2 Region footprint 360
14.5.5.3 Therapy type footprint 361
14.5.5.4 Therapeutic area footprint 362
14.5.5.5 Route of administration footprint 363
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 364
14.6.1 PROGRESSIVE COMPANIES 364
14.6.2 RESPONSIVE COMPANIES 364
14.6.3 DYNAMIC COMPANIES 364
14.6.4 STARTING BLOCKS 364
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 366
14.6.5.1 Detailed list of key startups/SMEs 366
14.6.5.2 Competitive benchmarking of key startups/SMEs 367
14.7 VALUATION & FINANCIAL METRICS 368
14.7.1 FINANCIAL METRICS 368
14.7.2 COMPANY VALUATION 368
14.8 BRAND/PRODUCT COMPARISON 369
14.9 COMPETITIVE SCENARIO 370
14.9.1 PRODUCT APPROVALS 370
14.9.2 DEALS 371
14.9.3 EXPANSIONS 373
15 COMPANY PROFILES 374
15.1 INTRODUCTION 374
15.2 KEY PLAYERS 374
15.2.1 BIOGEN INC. 374
15.2.1.1 Business overview 374
15.2.1.2 Products offered 375
15.2.1.3 Recent developments 376
15.2.1.3.1 Deals 376
15.2.1.4 MnM view 376
15.2.1.4.1 Key strengths 376
15.2.1.4.2 Strategic choices 377
15.2.1.4.3 Weaknesses and competitive threats 377
15.2.2 NOVARTIS AG 378
15.2.2.1 Business overview 378
15.2.2.2 Products offered 379
15.2.2.3 Recent developments 380
15.2.2.3.1 Deals 380
15.2.2.3.2 Expansions 380
15.2.2.3.3 Other developments 381
15.2.2.4 MnM view 381
15.2.2.4.1 Key strengths 381
15.2.2.4.2 Strategic choices 381
15.2.2.4.3 Weaknesses and competitive threats 381
15.2.3 ALNYLAM PHARMACEUTICALS, INC. 382
15.2.3.1 Business overview 382
15.2.3.2 Products offered 383
15.2.3.3 Recent developments 384
15.2.3.3.1 Product approvals 384
15.2.3.3.2 Deals 384
15.2.3.3.3 Other developments 385
15.2.3.4 MnM view 385
15.2.3.4.1 Key strengths 385
15.2.3.4.2 Strategic choices 385
15.2.3.4.3 Weaknesses and competitive threats 385
15.2.4 SAREPTA THERAPEUTICS, INC. 386
15.2.4.1 Business overview 386
15.2.4.2 Products offered 387
15.2.4.3 Recent developments 388
15.2.4.3.1 Product approvals 388
15.2.4.3.2 Deals 388
15.2.4.4 MnM view 389
15.2.4.4.1 Key strengths 389
15.2.4.4.2 Strategic choices 389
15.2.4.4.3 Weaknesses and competitive threats 389
15.2.5 JAZZ PHARMACEUTICALS PLC 390
15.2.5.1 Business overview 390
15.2.5.2 Products offered 391
15.2.5.3 Recent developments 392
15.2.5.3.1 Expansions 392
15.2.5.4 MnM view 392
15.2.5.4.1 Key strengths 392
15.2.5.4.2 Strategic choices 392
15.2.5.4.3 Weaknesses and competitive threats 392
15.2.6 FERRING B.V. 393
15.2.6.1 Business overview 393
15.2.6.2 Products offered 394
15.2.6.3 Recent developments 394
15.2.6.3.1 Product approvals 394
15.2.6.3.2 Deals 394
15.2.6.3.3 Expansions 395
15.2.7 PFIZER INC. 396
15.2.7.1 Business overview 396
15.2.7.2 Products offered 397
15.2.7.3 Recent developments 398
15.2.7.3.1 Product approvals 398
15.2.7.3.2 Deals 398
15.2.8 AMGEN, INC. 399
15.2.8.1 Business overview 399
15.2.8.2 Products offered 400
15.2.8.3 Recent developments 400
15.2.8.3.1 Deals 400
15.2.8.3.2 Expansions 400
15.2.9 JOHNSON & JOHNSON SERVICES, INC. 401
15.2.9.1 Business overview 401
15.2.9.2 Products offered 402
15.2.9.3 Recent developments 402
15.2.9.3.1 Deals 402
15.2.9.3.2 Other developments 403
15.2.10 DAIICHI SANKYO COMPANY, LIMITED. 404
15.2.10.1 Business overview 404
15.2.10.2 Products offered 405
15.2.11 BIOMARIN PHARMACEUTICAL INC. 406
15.2.11.1 Business overview 406
15.2.11.2 Products offered 407
15.2.11.3 Recent developments 407
15.2.11.3.1 Product approvals 407
15.2.11.3.2 Expansions 408
15.2.12 KYOWA KIRIN CO., LTD. 409
15.2.12.1 Business overview 409
15.2.12.2 Products offered 410
15.2.12.3 Recent developments 411
15.2.12.3.1 Product approvals 411
15.2.12.3.2 Deals 411
15.2.13 NIPPON SHINYAKU CO., LTD. 412
15.2.13.1 Business overview 412
15.2.13.2 Products offered 413
15.2.13.3 Recent developments 414
15.2.13.3.1 Deals 414
15.2.14 PTC THERAPEUTICS 415
15.2.14.1 Business overview 415
15.2.14.2 Products offered 416
15.2.14.3 Recent developments 416
15.2.14.3.1 Product approvals 416
15.2.15 UNIQURE NV. 417
15.2.15.1 Business overview 417
15.2.15.2 Products offered 418
15.2.15.3 Recent developments 418
15.2.15.3.1 Deals 418
15.3 OTHER PLAYERS 419
15.3.1 JUVENTAS CELL THERAPY LTD. 419
15.3.2 CRISPR THERAPEUTICS 419
15.3.3 BLUEBIRD BIO, INC. 420
15.3.4 KRYSTAL BIOTECH, INC. 421
15.3.5 SHANGHAI SUNWAY BIOTECH CO., LTD. 421
15.3.6 JW (CAYMAN) THERAPEUTICS CO. LTD 422
15.3.7 IASO BIOTECHNOLOGY 422
15.3.8 CARSGEN THERAPEUTICS HOLDINGS LIMITED 423
15.3.9 ADAPTIMMUNE 423
15.3.10 SIBIONO GENETECH CO. LTD. 424
15.3.11 ULTRAGENYX PHARMACEUTICAL INC. 424
16 APPENDIX 425
16.1 DISCUSSION GUIDE 425
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 430
16.3 CUSTOMIZATION OPTIONS 432
16.4 RELATED REPORTS 432
16.5 AUTHOR DETAILS 433
LIST OF TABLES
TABLE 1 GENE THERAPY MARKET: INCLUSIONS & EXCLUSIONS 43
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 55
TABLE 3 GENE THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 68
TABLE 4 GENE THERAPY MARKET: KEY PRODUCT APPROVALS, 2022–2024 69
TABLE 5 GENE THERAPY MARKET: INVESTMENTS AND FINANCING BY STARTUPS, 2024 70
TABLE 6 GENE THERAPY MARKET: LIST OF ADVANCED PLATFORMS LAUNCHED IN
2022–2024 71
TABLE 7 NUMBER OF CLINICAL TRIALS FOR GENE THERAPY DRUGS, 2024 72
TABLE 8 COST OF KEY GENE THERAPY PRODUCTS, 2024 73
TABLE 9 GENE THERAPY MARKET: RAW MATERIAL VENDORS 83
TABLE 10 GENE THERAPY MARKET: PRODUCT VENDORS 83
TABLE 11 GENE THERAPY MARKET: ROLE OF END USERS 84
TABLE 12 GENE THERAPY MARKET: REGULATORY BODIES 84
TABLE 13 GENE THERAPY MARKET: INDICATIVE LIST OF PATENTS, 2023–2024 87
TABLE 14 GENE THERAPY PRODUCTS IN CLINICAL PIPELINE 88
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 19 COUNTRY-WISE REGULATORY SCENARIO FOR GENE THERAPY PRODUCTS 91
TABLE 20 US: REIMBURSEMENT CODES FOR GENE THERAPY PRODUCTS 93
TABLE 21 EUROPE: REIMBURSEMENT SCENARIO FOR GENE THERAPY PRODUCTS,
BY COUNTRY 94
TABLE 22 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY KEY PLAYER,
2022–2024 (USD) 95
TABLE 23 AVERAGE SELLING PRICE TREND OF GENE THERAPIES, BY REGION,
2022–2024 (USD) 97
TABLE 24 GENE THERAPY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 99
TABLE 25 GENE THERAPY MARKET: IMPACT OF PORTER’S FIVE FORCES 100
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 103
TABLE 27 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER 104
TABLE 28 GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 109
TABLE 29 GENE SILENCING THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 110
TABLE 30 NORTH AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 110
TABLE 31 EUROPE: GENE SILENCING THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 111
TABLE 32 ASIA PACIFIC: GENE SILENCING THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 111
TABLE 33 LATIN AMERICA: GENE SILENCING THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 112
TABLE 34 MIDDLE EAST: GENE SILENCING THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 112
TABLE 35 GCC COUNTRIES: GENE SILENCING THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 112
TABLE 36 CELL REPLACEMENT THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 113
TABLE 37 NORTH AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 114
TABLE 38 EUROPE: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 114
TABLE 39 ASIA PACIFIC: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 115
TABLE 40 LATIN AMERICA: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 115
TABLE 41 MIDDLE EAST: CELL REPLACEMENT THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 115
TABLE 42 GCC COUNTRIES: CELL REPLACEMENT THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 116
TABLE 43 GENE AUGMENTATION THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 117
TABLE 44 NORTH AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 117
TABLE 45 EUROPE: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 118
TABLE 46 ASIA PACIFIC: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 118
TABLE 47 LATIN AMERICA: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 119
TABLE 48 MIDDLE EAST: GENE AUGMENTATION THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 119
TABLE 49 GCC COUNTRIES: GENE AUGMENTATION THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 119
TABLE 50 OTHER GENE THERAPIES MARKET, BY REGION, 2022–2032 (USD MILLION) 120
TABLE 51 NORTH AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 121
TABLE 52 EUROPE: OTHER GENE THERAPIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 121
TABLE 53 ASIA PACIFIC: OTHER GENE THERAPIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 122
TABLE 54 LATIN AMERICA: OTHER GENE THERAPIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 122
TABLE 55 MIDDLE EAST: OTHER GENE THERAPIES MARKET, BY REGION,
2022–2032 (USD MILLION) 122
TABLE 56 GCC COUNTRIES: OTHER GENE THERAPIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 123
TABLE 57 GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 125
TABLE 58 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 126
TABLE 59 VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 126
TABLE 60 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 126
TABLE 61 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 127
TABLE 62 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 127
TABLE 63 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 128
TABLE 64 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 128
TABLE 65 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 128
TABLE 66 RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 129
TABLE 67 RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 129
TABLE 68 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 130
TABLE 69 EUROPE: RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 130
TABLE 70 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 131
TABLE 71 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 131
TABLE 72 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 131
TABLE 73 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 132
TABLE 74 GAMMA RETROVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 132
TABLE 75 NORTH AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 133
TABLE 76 EUROPE: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 133
TABLE 77 ASIA PACIFIC: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 134
TABLE 78 LATIN AMERICA: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 134
TABLE 79 MIDDLE EAST: GAMMA RETROVIRAL VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 134
TABLE 80 GCC COUNTRIES: GAMMA RETROVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 135
TABLE 81 LENTIVIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 136
TABLE 82 NORTH AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 136
TABLE 83 EUROPE: LENTIVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 136
TABLE 84 ASIA PACIFIC: LENTIVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 137
TABLE 85 LATIN AMERICA: LENTIVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 137
TABLE 86 MIDDLE EAST: LENTIVIRAL VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 137
TABLE 87 GCC COUNTRIES: LENTIVIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 138
TABLE 88 AAV VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 138
TABLE 89 NORTH AMERICA: AAV VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 139
TABLE 90 EUROPE: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 139
TABLE 91 ASIA PACIFIC: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 140
TABLE 92 LATIN AMERICA: AAV VECTORS MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 140
TABLE 93 MIDDLE EAST: AAV VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 140
TABLE 94 GCC COUNTRIES: AAV VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 141
TABLE 95 OTHER VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 141
TABLE 96 NORTH AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 142
TABLE 97 EUROPE: OTHER VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 142
TABLE 98 ASIA PACIFIC: OTHER VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 143
TABLE 99 LATIN AMERICA: OTHER VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 143
TABLE 100 MIDDLE EAST: OTHER VIRAL VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 143
TABLE 101 GCC COUNTRIES: OTHER VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 144
TABLE 102 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 144
TABLE 103 NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 145
TABLE 104 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 145
TABLE 105 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 146
TABLE 106 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 146
TABLE 107 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 147
TABLE 108 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 147
TABLE 109 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 147
TABLE 110 OLIGONUCLEOTIDE VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 148
TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 148
TABLE 112 EUROPE: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 149
TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 149
TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 150
TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 150
TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 150
TABLE 117 OTHER NON-VIRAL VECTORS MARKET, BY REGION, 2022–2032 (USD MILLION) 151
TABLE 118 NORTH AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 151
TABLE 119 EUROPE: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 152
TABLE 120 ASIA PACIFIC: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 152
TABLE 121 LATIN AMERICA: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 153
TABLE 122 MIDDLE EAST: OTHER NON-VIRAL VECTORS MARKET, BY REGION,
2022–2032 (USD MILLION) 153
TABLE 123 GCC COUNTRIES: OTHER NON-VIRAL VECTORS MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 153
TABLE 124 GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 155
TABLE 125 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 156
TABLE 126 NORTH AMERICA: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 156
TABLE 127 EUROPE: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 157
TABLE 128 ASIA PACIFIC: DEFICIENCY GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 157
TABLE 129 LATIN AMERICA: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022–2032 (USD MILLION) 158
TABLE 130 MIDDLE EAST: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY REGION, 2022–2032 (USD MILLION) 158
TABLE 131 GCC COUNTRIES: GENE THERAPY MARKET FOR DEFICIENCY GENES, BY COUNTRY, 2022–2032 (USD MILLION) 158
TABLE 132 RECEPTOR GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 159
TABLE 133 NORTH AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 159
TABLE 134 EUROPE: RECEPTOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 160
TABLE 135 ASIA PACIFIC: RECEPTOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 160
TABLE 136 LATIN AMERICA: RECEPTOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 161
TABLE 137 MIDDLE EAST: RECEPTOR GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 161
TABLE 138 GCC COUNTRIES: RECEPTOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 161
TABLE 139 ANTIGEN GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 162
TABLE 140 NORTH AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 163
TABLE 141 EUROPE: ANTIGEN GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 163
TABLE 142 ASIA PACIFIC: ANTIGEN GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 164
TABLE 143 LATIN AMERICA: ANTIGEN GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 164
TABLE 144 MIDDLE EAST: ANTIGEN GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 164
TABLE 145 GCC COUNTRIES: ANTIGEN GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 165
TABLE 146 CYTOKINE GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 166
TABLE 147 NORTH AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 166
TABLE 148 EUROPE: CYTOKINE GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 167
TABLE 149 ASIA PACIFIC: CYTOKINE GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 167
TABLE 150 LATIN AMERICA: CYTOKINE GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 168
TABLE 151 MIDDLE EAST: CYTOKINE GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 168
TABLE 152 GCC COUNTRIES: CYTOKINE GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 168
TABLE 153 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 169
TABLE 154 NORTH AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 170
TABLE 155 EUROPE: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 170
TABLE 156 ASIA PACIFIC: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 171
TABLE 157 LATIN AMERICA: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 171
TABLE 158 MIDDLE EAST: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 171
TABLE 159 GCC COUNTRIES: TUMOR SUPPRESSOR GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 172
TABLE 160 GENE THERAPY MARKET FOR OTHER GENES, BY REGION,
2022–2032 (USD MILLION) 173
TABLE 161 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 173
TABLE 162 EUROPE: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY,
2022–2032 (USD MILLION) 174
TABLE 163 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY,
2022–2032 (USD MILLION) 174
TABLE 164 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 175
TABLE 165 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER GENES, BY REGION,
2022–2032 (USD MILLION) 175
TABLE 166 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER GENES, BY COUNTRY, 2022–2032 (USD MILLION) 175
TABLE 167 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 177
TABLE 168 GENE THERAPY MARKET FOR NEUROLOGY, BY REGION,
2022–2032 (USD MILLION) 178
TABLE 169 NORTH AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 178
TABLE 170 EUROPE: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 179
TABLE 171 ASIA PACIFIC: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 179
TABLE 172 LATIN AMERICA: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 180
TABLE 173 MIDDLE EAST: GENE THERAPY MARKET FOR NEUROLOGY, BY REGION,
2022–2032 (USD MILLION) 180
TABLE 174 GCC COUNTRIES: GENE THERAPY MARKET FOR NEUROLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 180
TABLE 175 GENE THERAPY MARKET FOR ONCOLOGY, BY REGION, 2022–2032 (USD MILLION) 181
TABLE 176 NORTH AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 182
TABLE 177 EUROPE: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 182
TABLE 178 ASIA PACIFIC: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 183
TABLE 179 LATIN AMERICA: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 183
TABLE 180 MIDDLE EAST: GENE THERAPY MARKET FOR ONCOLOGY, BY REGION,
2022–2032 (USD MILLION) 183
TABLE 181 GCC COUNTRIES: GENE THERAPY MARKET FOR ONCOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 184
TABLE 182 GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION,
2022–2032 (USD MILLION) 185
TABLE 183 NORTH AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 185
TABLE 184 EUROPE: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 186
TABLE 185 ASIA PACIFIC: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 186
TABLE 186 LATIN AMERICA: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY,
2022–2032 (USD MILLION) 187
TABLE 187 MIDDLE EAST: GENE THERAPY MARKET FOR HEMATOLOGY, BY REGION,
2022–2032 (USD MILLION) 187
TABLE 188 GCC COUNTRIES: GENE THERAPY MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2032 (USD MILLION) 187
TABLE 189 GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,
2022–2032 (USD MILLION) 188
TABLE 190 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2032 (USD MILLION) 188
TABLE 191 EUROPE: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2032 (USD MILLION) 189
TABLE 192 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2032 (USD MILLION) 189
TABLE 193 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2032 (USD MILLION) 190
TABLE 194 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2022–2032 (USD MILLION) 190
TABLE 195 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2022–2032 (USD MILLION) 190
TABLE 196 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 192
TABLE 197 IN VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS 193
TABLE 198 IN VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 193
TABLE 199 NORTH AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 194
TABLE 200 EUROPE: IN VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 194
TABLE 201 ASIA PACIFIC: IN VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 195
TABLE 202 LATIN AMERICA: IN VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 195
TABLE 203 MIDDLE EAST: IN VIVO GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 195
TABLE 204 GCC COUNTRIES: IN VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 196
TABLE 205 EX VIVO GENE THERAPY: COMMERCIALIZED AND PIPELINE PRODUCTS 197
TABLE 206 EX VIVO GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 197
TABLE 207 NORTH AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 197
TABLE 208 EUROPE: EX VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 198
TABLE 209 APAC: EX VIVO GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 198
TABLE 210 LATIN AMERICA: EX VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 199
TABLE 211 MIDDLE EAST: EX VIVO GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 199
TABLE 212 GCC COUNTRIES: EX VIVO GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 199
TABLE 213 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 201
TABLE 214 EXAMPLES OF INTRAVENOUSLY DELIVERED GENE THERAPY 201
TABLE 215 INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 202
TABLE 216 NORTH AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 202
TABLE 217 EUROPE: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 203
TABLE 218 ASIA PACIFIC: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 203
TABLE 219 LATIN AMERICA: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 204
TABLE 220 MIDDLE EAST: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET,
BY REGION, 2022–2032 (USD MILLION) 204
TABLE 221 GCC COUNTRIES: INTRAVENOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 204
TABLE 222 SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET, BY REGION,
2022–2032 (USD MILLION) 205
TABLE 223 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 206
TABLE 224 EUROPE: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 206
TABLE 225 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 207
TABLE 226 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 207
TABLE 227 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY REGION, 2022–2032 (USD MILLION) 207
TABLE 228 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GENE THERAPY MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 208
TABLE 229 EXAMPLE OF GENE THERAPIES ADMINISTERED THROUGH OTHER ROUTES 208
TABLE 230 GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION) 209
TABLE 231 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 209
TABLE 232 EUROPE: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY COUNTRY, 2022–2032 (USD MILLION) 210
TABLE 233 ASIA PACIFIC: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 210
TABLE 234 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 211
TABLE 235 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION) 211
TABLE 236 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 211
TABLE 237 GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 213
TABLE 238 GENE THERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2032 (USD MILLION) 214
TABLE 239 NORTH AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 214
TABLE 240 EUROPE: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 215
TABLE 241 ASIA PACIFIC: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 215
TABLE 242 LATIN AMERICA: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 216
TABLE 243 MIDDLE EAST: GENE THERAPY MARKET FOR HOSPITALS, BY REGION,
2022–2032 (USD MILLION) 216
TABLE 244 GCC COUNTRIES: GENE THERAPY MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 216
TABLE 245 GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION,
2022–2032 (USD MILLION) 217
TABLE 246 NORTH AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2022–2032 (USD MILLION) 218
TABLE 247 EUROPE: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY,
2022–2032 (USD MILLION) 218
TABLE 248 ASIA PACIFIC: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 219
TABLE 249 LATIN AMERICA: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 219
TABLE 250 MIDDLE EAST: GENE THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2032 (USD MILLION) 219
TABLE 251 GCC COUNTRIES: GENE THERAPY MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2022–2032 (USD MILLION) 220
TABLE 252 GENE THERAPY MARKET FOR OTHER END USERS, BY REGION,
2022–2032 (USD MILLION) 221
TABLE 253 NORTH AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 221
TABLE 254 EUROPE: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY,
2022–2032 (USD MILLION) 222
TABLE 255 ASIA PACIFIC GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 222
TABLE 256 LATIN AMERICA: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 223
TABLE 257 MIDDLE EAST: GENE THERAPY MARKET FOR OTHER END USERS, BY REGION, 2022–2032 (USD MILLION) 223
TABLE 258 GCC COUNTRIES: GENE THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2032 (USD MILLION) 223
TABLE 259 GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 225
TABLE 260 NORTH AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 226
TABLE 261 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 227
TABLE 262 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 228
TABLE 263 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 228
TABLE 264 NORTH AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 228
TABLE 265 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 229
TABLE 266 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 229
TABLE 267 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 229
TABLE 268 NORTH AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 230
TABLE 269 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 230
TABLE 270 NORTH AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 230
TABLE 271 NORTH AMERICA: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 231
TABLE 272 US FDA APPROVALS FOR GENE THERAPY PRODUCTS, 2022–2024 232
TABLE 273 US: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 232
TABLE 274 US: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 233
TABLE 275 US: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 233
TABLE 276 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 233
TABLE 277 US: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 234
TABLE 278 US: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 234
TABLE 279 US: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 234
TABLE 280 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 235
TABLE 281 US: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 235
TABLE 282 US: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 235
TABLE 283 CANADA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 236
TABLE 284 CANADA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 236
TABLE 285 CANADA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 237
TABLE 286 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 237
TABLE 287 CANADA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 237
TABLE 288 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 238
TABLE 289 CANADA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 238
TABLE 290 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 238
TABLE 291 CANADA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 239
TABLE 292 CANADA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 239
TABLE 293 EUROPE: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 240
TABLE 294 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 242
TABLE 295 EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 242
TABLE 296 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 242
TABLE 297 EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 243
TABLE 298 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 243
TABLE 299 EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 243
TABLE 300 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 244
TABLE 301 EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 244
TABLE 302 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 244
TABLE 303 EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 245
TABLE 304 EUROPE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 245
TABLE 305 GERMANY: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 246
TABLE 306 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 246
TABLE 307 GERMANY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 246
TABLE 308 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 247
TABLE 309 GERMANY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 247
TABLE 310 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 247
TABLE 311 GERMANY: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 248
TABLE 312 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 248
TABLE 313 GERMANY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 248
TABLE 314 GERMANY: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 249
TABLE 315 UK: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 249
TABLE 316 UK: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 250
TABLE 317 UK: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 250
TABLE 318 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 250
TABLE 319 UK: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 251
TABLE 320 UK: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 251
TABLE 321 UK: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 251
TABLE 322 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 252
TABLE 323 UK: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 252
TABLE 324 UK: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 252
TABLE 325 FRANCE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 253
TABLE 326 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 254
TABLE 327 FRANCE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 254
TABLE 328 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 254
TABLE 329 FRANCE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 255
TABLE 330 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 255
TABLE 331 FRANCE: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 255
TABLE 332 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 256
TABLE 333 FRANCE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 256
TABLE 334 FRANCE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 256
TABLE 335 ITALY: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 257
TABLE 336 ITALY: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 257
TABLE 337 ITALY: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 258
TABLE 338 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 258
TABLE 339 ITALY: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 258
TABLE 340 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 259
TABLE 341 ITALY: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 259
TABLE 342 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 259
TABLE 343 ITALY: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 260
TABLE 344 ITALY: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 260
TABLE 345 SPAIN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 261
TABLE 346 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 261
TABLE 347 SPAIN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 261
TABLE 348 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 262
TABLE 349 SPAIN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 262
TABLE 350 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 262
TABLE 351 SPAIN: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 263
TABLE 352 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 263
TABLE 353 SPAIN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 263
TABLE 354 SPAIN: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 264
TABLE 355 SWITZERLAND: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 264
TABLE 356 SWITZERLAND: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 265
TABLE 357 SWITZERLAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 265
TABLE 358 SWITZERLAND: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 265
TABLE 359 SWITZERLAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 266
TABLE 360 SWITZERLAND: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 266
TABLE 361 SWITZERLAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 266
TABLE 362 SWITZERLAND: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 267
TABLE 363 SWITZERLAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 267
TABLE 364 SWITZERLAND: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 267
TABLE 365 NETHERLANDS: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 268
TABLE 366 NETHERLANDS: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 268
TABLE 367 NETHERLANDS: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 269
TABLE 368 NETHERLANDS: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 269
TABLE 369 NETHERLANDS: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 269
TABLE 370 NETHERLANDS: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 270
TABLE 371 NETHERLANDS: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 270
TABLE 372 NETHERLANDS: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 270
TABLE 373 NETHERLANDS: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 271
TABLE 374 NETHERLANDS: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 271
TABLE 375 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 272
TABLE 376 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 272
TABLE 377 REST OF EUROPE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 272
TABLE 378 REST OF EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 273
TABLE 379 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 273
TABLE 380 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 273
TABLE 381 REST OF EUROPE: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 274
TABLE 382 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 274
TABLE 383 REST OF EUROPE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 274
TABLE 384 REST OF EUROPE: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 275
TABLE 385 ASIA PACIFIC: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 276
TABLE 386 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 277
TABLE 387 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 277
TABLE 388 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 277
TABLE 389 ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 278
TABLE 390 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 278
TABLE 391 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 278
TABLE 392 ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 279
TABLE 393 ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 279
TABLE 394 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 279
TABLE 395 ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 280
TABLE 396 ASIA PACIFIC: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 280
TABLE 397 CHINA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 281
TABLE 398 CHINA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 281
TABLE 399 CHINA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 281
TABLE 400 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 282
TABLE 401 CHINA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 282
TABLE 402 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 282
TABLE 403 CHINA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 283
TABLE 404 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 283
TABLE 405 CHINA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 283
TABLE 406 CHINA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 284
TABLE 407 JAPAN: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 285
TABLE 408 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 285
TABLE 409 JAPAN: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 285
TABLE 410 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 286
TABLE 411 JAPAN: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 286
TABLE 412 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 286
TABLE 413 JAPAN: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 287
TABLE 414 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 287
TABLE 415 JAPAN: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 287
TABLE 416 JAPAN: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 288
TABLE 417 INDIA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 289
TABLE 418 INDIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 289
TABLE 419 INDIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 289
TABLE 420 INDIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 290
TABLE 421 INDIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 290
TABLE 422 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 290
TABLE 423 INDIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 291
TABLE 424 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 291
TABLE 425 INDIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 291
TABLE 426 INDIA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 292
TABLE 427 AUSTRALIA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 292
TABLE 428 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 293
TABLE 429 AUSTRALIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 293
TABLE 430 AUSTRALIA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 293
TABLE 431 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 294
TABLE 432 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 294
TABLE 433 AUSTRALIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 294
TABLE 434 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 295
TABLE 435 AUSTRALIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 295
TABLE 436 AUSTRALIA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 295
TABLE 437 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 296
TABLE 438 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 296
TABLE 439 SOUTH KOREA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 297
TABLE 440 SOUTH KOREA: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 297
TABLE 441 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 297
TABLE 442 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 298
TABLE 443 SOUTH KOREA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 298
TABLE 444 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 298
TABLE 445 SOUTH KOREA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 299
TABLE 446 SOUTH KOREA: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 299
TABLE 447 THAILAND: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 300
TABLE 448 THAILAND: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 300
TABLE 449 THAILAND: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 300
TABLE 450 THAILAND: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 301
TABLE 451 THAILAND: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 301
TABLE 452 THAILAND: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 301
TABLE 453 THAILAND: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 302
TABLE 454 THAILAND: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 302
TABLE 455 THAILAND: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 302
TABLE 456 THAILAND: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 303
TABLE 457 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 303
TABLE 458 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 304
TABLE 459 REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 304
TABLE 460 REST OF ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE
2022–2032 (USD MILLION) 304
TABLE 461 REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY TYPE, 2022–2032 (USD MILLION) 305
TABLE 462 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 305
TABLE 463 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 305
TABLE 464 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 306
TABLE 465 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 306
TABLE 466 REST OF ASIA PACIFIC: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 306
TABLE 467 LATIN AMERICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 308
TABLE 468 LATIN AMERICA: GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 308
TABLE 469 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 308
TABLE 470 LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 309
TABLE 471 LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 309
TABLE 472 LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 309
TABLE 473 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 310
TABLE 474 LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 310
TABLE 475 LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 310
TABLE 476 LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 311
TABLE 477 LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 311
TABLE 478 LATIN AMERICA: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 311
TABLE 479 BRAZIL: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 312
TABLE 480 BRAZIL: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 312
TABLE 481 BRAZIL: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 313
TABLE 482 BRAZIL: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 313
TABLE 483 BRAZIL: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 313
TABLE 484 BRAZIL: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 314
TABLE 485 BRAZIL: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 314
TABLE 486 BRAZIL: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 314
TABLE 487 BRAZIL: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 315
TABLE 488 BRAZIL: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 315
TABLE 489 MEXICO: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 316
TABLE 490 MEXICO: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 316
TABLE 491 MEXICO: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 316
TABLE 492 MEXICO: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 317
TABLE 493 MEXICO: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 317
TABLE 494 MEXICO: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 317
TABLE 495 MEXICO: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 318
TABLE 496 MEXICO: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 318
TABLE 497 MEXICO: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 318
TABLE 498 MEXICO: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 319
TABLE 499 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 319
TABLE 500 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 320
TABLE 501 REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 320
TABLE 502 REST OF LATIN AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 320
TABLE 503 REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY TYPE, 2022–2032 (USD MILLION) 321
TABLE 504 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 321
TABLE 505 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 321
TABLE 506 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 322
TABLE 507 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 322
TABLE 508 REST OF LATIN AMERICA: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 322
TABLE 509 MIDDLE EAST: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 324
TABLE 510 MIDDLE EAST: GENE THERAPY MARKET, BY REGION, 2022–2032 (USD MILLION) 324
TABLE 511 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 324
TABLE 512 MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 325
TABLE 513 MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 325
TABLE 514 MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 325
TABLE 515 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 326
TABLE 516 MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 326
TABLE 517 MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 326
TABLE 518 MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 327
TABLE 519 MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 327
TABLE 520 MIDDLE EAST: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 327
TABLE 521 GCC COUNTRIES: GENE THERAPY MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 328
TABLE 522 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 328
TABLE 523 GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 329
TABLE 524 GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 329
TABLE 525 GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 329
TABLE 526 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 330
TABLE 527 GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 330
TABLE 528 GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 330
TABLE 529 GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 331
TABLE 530 GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 331
TABLE 531 GCC COUNTRIES: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 331
TABLE 532 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 332
TABLE 533 SAUDI ARABIA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 333
TABLE 534 SAUDI ARABIA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 333
TABLE 535 SAUDI ARABIA: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 333
TABLE 536 SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 334
TABLE 537 SAUDI ARABIA: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 334
TABLE 538 SAUDI ARABIA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 334
TABLE 539 SAUDI ARABIA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 335
TABLE 540 SAUDI ARABIA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 335
TABLE 541 SAUDI ARABIA: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 335
TABLE 542 UAE: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 336
TABLE 543 UAE: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 336
TABLE 544 UAE: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 337
TABLE 545 UAE: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 337
TABLE 546 UAE: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 337
TABLE 547 UAE: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 338
TABLE 548 UAE: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 338
TABLE 549 UAE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 338
TABLE 550 UAE: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 339
TABLE 551 UAE: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 339
TABLE 552 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 340
TABLE 553 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 340
TABLE 554 REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY TYPE, 2022–2032 (USD MILLION) 340
TABLE 555 REST OF GCC COUNTRIES: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 341
TABLE 556 REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY TYPE, 2022–2032 (USD MILLION) 341
TABLE 557 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 341
TABLE 558 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2022–2032 (USD MILLION) 342
TABLE 559 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY DELIVERY METHOD, 2022–2032 (USD MILLION) 342
TABLE 560 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 342
TABLE 561 REST OF GCC COUNTRIES: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 343
TABLE 562 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPY TYPE,
2022–2032 (USD MILLION) 343
TABLE 563 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY VECTOR,
2022–2032 (USD MILLION) 344
TABLE 564 REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE, 2022–2032 (USD MILLION) 344
TABLE 565 REST OF MIDDLE EAST: RETROVIRAL VECTORS MARKET, BY TYPE,
2022–2032 (USD MILLION) 344
TABLE 566 REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET,
BY TYPE, 2022–2032 (USD MILLION) 345
TABLE 567 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY GENE TYPE,
2022–2032 (USD MILLION) 345
TABLE 568 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 345
TABLE 569 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 346
TABLE 570 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 346
TABLE 571 REST OF MIDDLE EAST: GENE THERAPY MARKET, BY END USER,
2022–2032 (USD MILLION) 346
TABLE 572 AFRICA: MACROECONOMIC OUTLOOK FOR GENE THERAPY MARKET 348
TABLE 573 AFRICA: GENE THERAPY MARKET, BY THERAPY TYPE, 2022–2032 (USD MILLION) 348
TABLE 574 AFRICA: GENE THERAPY MARKET, BY VECTOR, 2022–2032 (USD MILLION) 349
TABLE 575 AFRICA: VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 349
TABLE 576 AFRICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2022–2032 (USD MILLION) 349
TABLE 577 AFRICA: NON-VIRAL VECTOR-BASED GENE THERAPY MARKET, BY TYPE,
2022–2032 (USD MILLION) 350
TABLE 578 AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2022–2032 (USD MILLION) 350
TABLE 579 AFRICA: GENE THERAPY MARKET, BY THERAPEUTIC AREA,
2022–2032 (USD MILLION) 350
TABLE 580 AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2022–2032 (USD MILLION) 351
TABLE 581 AFRICA: GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 351
TABLE 582 AFRICA: GENE THERAPY MARKET, BY END USER, 2022–2032 (USD MILLION) 351
TABLE 583 STRATEGIES DEPLOYED BY KEY COMPANIES IN GENE THERAPY MARKET 352
TABLE 584 GENE THERAPY MARKET: DEGREE OF COMPETITION 355
TABLE 585 GENE THERAPY MARKET: REGION FOOTPRINT 360
TABLE 586 GENE THERAPY MARKET: THERAPY TYPE FOOTPRINT 361
TABLE 587 GENE THERAPY MARKET: THERAPEUTIC AREA FOOTPRINT 362
TABLE 588 GENE THERAPY MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 363
TABLE 589 GENE THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 366
TABLE 590 GENE THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 367
TABLE 591 GENE THERAPY MARKET: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2024 370
TABLE 592 GENE THERAPY MARKET: DEALS, JANUARY 2022–DECEMBER 2024 371
TABLE 593 GENE THERAPY MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2024 373
TABLE 594 BIOGEN: COMPANY OVERVIEW 374
TABLE 595 BIOGEN: PRODUCTS OFFERED 375
TABLE 596 BIOGEN: DEALS, JANUARY 2022–DECEMBER 2024 376
TABLE 597 NOVARTIS: COMPANY OVERVIEW 378
TABLE 598 NOVARTIS: PRODUCTS OFFERED 379
TABLE 599 NOVARTIS: DEALS, JANUARY 2022–DECEMBER 2024 380
TABLE 600 NOVARTIS: EXPANSIONS, JANUARY 2022–DECEMBER 2024 380
TABLE 601 NOVARTIS: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2024 381
TABLE 602 ALNYLAM PHARMACEUTICALS: COMPANY OVERVIEW 382
TABLE 603 ALNYLAM PHARMACEUTICALS: PRODUCTS OFFERED 383
TABLE 604 ALNYLAM PHARMACEUTICALS: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2024 384
TABLE 605 ALNYLAM PHARMACEUTICALS: DEALS, JANUARY 2022–DECEMBER 2024 384
TABLE 606 ALNYLAM PHARMACEUTICALS: OTHER DEVELOPMENTS,
JANUARY 2022–DECEMBER 2024 385
TABLE 607 SAREPTA THERAPEUTICS: COMPANY OVERVIEW 386
TABLE 608 SAREPTA THERAPEUTICS: PRODUCTS OFFERED 387
TABLE 609 SAREPTA THERAPEUTICS: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2024 388
TABLE 610 SAREPTA THERAPEUTICS: DEALS, JANUARY 2022–DECEMBER 2024 388
TABLE 611 JAZZ PHARMACEUTICALS: COMPANY OVERVIEW 390
TABLE 612 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED 391
TABLE 613 JAZZ PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–DECEMBER 2024 392
TABLE 614 FERRING: COMPANY OVERVIEW 393
TABLE 615 FERRING: PRODUCTS OFFERED 394
TABLE 616 FERRING: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 394
TABLE 617 FERRING: DEALS, JANUARY 2022–DECEMBER 2024 394
TABLE 618 FERRING: EXPANSIONS, JANUARY 2022–DECEMBER 2024 395
TABLE 619 PFIZER: COMPANY OVERVIEW 396
TABLE 620 PFIZER: PRODUCTS OFFERED 397
TABLE 621 PFIZER: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 398
TABLE 622 PFIZER: DEALS, JANUARY 2022–DECEMBER 2024 398
TABLE 623 AMGEN: COMPANY OVERVIEW 399
TABLE 624 AMGEN: PRODUCTS OFFERED 400
TABLE 625 AMGEN: DEALS, JANUARY 2022–DECEMBER 2024 400
TABLE 626 AMGEN: EXPANSIONS, JANUARY 2022–DECEMBER 2024 400
TABLE 627 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW 401
TABLE 628 JOHNSON & JOHNSON SERVICES: PRODUCTS OFFERED 402
TABLE 629 JOHNSON & JOHNSON SERVICES: DEALS, JANUARY 2022–DECEMBER 2024 402
TABLE 630 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2024 403
TABLE 631 DAIICHI SANKYO COMPANY: COMPANY OVERVIEW 404
TABLE 632 DAIICHI SANKYO COMPANY: PRODUCTS OFFERED 405
TABLE 633 BIOMARIN PHARMACEUTICAL: COMPANY OVERVIEW 406
TABLE 634 BIOMARIN PHARMACEUTICAL: PRODUCTS OFFERED 407
TABLE 635 BIOMARIN PHARMACEUTICAL: PRODUCT APPROVALS,
JANUARY 2022–DECEMBER 2024 407
TABLE 636 BIOMARIN PHARMACEUTICAL: EXPANSIONS, JANUARY 2022–DECEMBER 2024 408
TABLE 637 KYOWA KIRIN: COMPANY OVERVIEW 409
TABLE 638 KYOWA KIRIN: PRODUCTS OFFERED 410
TABLE 639 KYOWA KIRIN: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 411
TABLE 640 KYOWA KIRIN: DEALS, JANUARY 2022–DECEMBER 2024 411
TABLE 641 NIPPON SHINYAKU: COMPANY OVERVIEW 412
TABLE 642 NIPPON SHINYAKU: PRODUCTS OFFERED 413
TABLE 643 NIPPON SHINYAKU: DEALS, JANUARY 2022–DECEMBER 2024 414
TABLE 644 PTC THERAPEUTICS: COMPANY OVERVIEW 415
TABLE 645 PTC THERAPEUTICS: PRODUCTS OFFERED 416
TABLE 646 PTC THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2024 416
TABLE 647 UNIQURE: COMPANY OVERVIEW 417
TABLE 648 UNIQURE: PRODUCTS OFFERED 418
TABLE 649 UNIQURE: DEALS, JANUARY 2022–DECEMBER 2024 418
TABLE 650 JUVENTAS CELL THERAPY: COMPANY OVERVIEW 419
TABLE 651 CRISPR THERAPEUTICS: COMPANY OVERVIEW 419
TABLE 652 BLUEBIRD BIO: COMPANY OVERVIEW 420
TABLE 653 KRYSTAL BIOTECH: COMPANY OVERVIEW 421
TABLE 654 SHANGHAI SUNWAY BIOTECH: COMPANY OVERVIEW 421
TABLE 655 JW (CAYMAN) THERAPEUTICS: COMPANY OVERVIEW 422
TABLE 656 IASO BIOTECHNOLOGY: COMPANY OVERVIEW 422
TABLE 657 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW 423
TABLE 658 ADAPTIMMUNE: COMPANY OVERVIEW 423
TABLE 659 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW 424
TABLE 660 ULTRAGENYX PHARMACEUTICAL INC.: COMPANY OVERVIEW 424
LIST OF FIGURES
FIGURE 1 GENE THERAPY MARKET SEGMENTATION & REGIONAL SCOPE 42
FIGURE 2 GENE THERAPY MARKET: YEARS CONSIDERED 44
FIGURE 3 RESEARCH DESIGN 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: GENE THERAPY MARKET 49
FIGURE 5 GENE THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 51
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2023 52
FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOVARTIS AG: REVENUE SHARE ANALYSIS (2023) 52
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 53
FIGURE 9 GENE THERAPY MARKET: CAGR PROJECTIONS 55
FIGURE 10 DATA TRIANGULATION METHODOLOGY 57
FIGURE 11 GENE THERAPY MARKET, BY THERAPY TYPE, 2024 VS. 2032 (USD MILLION) 59
FIGURE 12 GENE THERAPY MARKET, BY VECTOR, 2024 VS. 2032 (USD MILLION) 60
FIGURE 13 GENE THERAPY MARKET, BY GENE TYPE, 2024 VS. 2032 (USD MILLION) 60
FIGURE 14 GENE THERAPY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2032 (USD MILLION) 61
FIGURE 15 GENE THERAPY MARKET, BY DELIVERY METHOD, 2024 VS. 2032 (USD MILLION) 61
FIGURE 16 GENE THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2024 62
FIGURE 17 GENE THERAPY MARKET, BY END USER, 2024 VS. 2032 (USD MILLION) 62
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF GENE THERAPY MARKET 63
FIGURE 19 INCREASING INVESTMENTS IN GENE THERAPY RESEARCH—A KEY FACTOR DRIVING GROWTH 64
FIGURE 20 GENE SILENCING THERAPY ACCOUNTED FOR LARGEST SHARE OF
NORTH AMERICAN MARKET IN 2024 65
FIGURE 21 HOSPITALS TO DOMINATE END-USER MARKET TILL 2032 66
FIGURE 22 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 66
FIGURE 23 GENE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67
FIGURE 24 GENE THERAPY MARKET: VALUE CHAIN ANALYSIS 80
FIGURE 25 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS 82
FIGURE 26 GENE THERAPY MARKET: ECOSYSTEM 82
FIGURE 27 PATENT ANALYSIS FOR GENE THERAPY MARKET,
JANUARY 2014–DECEMBER 2024 86
FIGURE 28 AVERAGE SELLING PRICE TREND OF GENE THERAPIES,
BY TYPE, 2022–2024 (USD) 96
FIGURE 29 AVERAGE SELLING PRICE OF GENE THERAPIES, BY REGION, 2023 (USD) 98
FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
FIGURE 31 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 101
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF GENE THERAPY PRODUCTS, BY DELIVERY METHOD 102
FIGURE 33 KEY BUYING CRITERIA FOR GENE THERAPY PRODUCTS, BY END USER 104
FIGURE 34 GENE THERAPY MARKET: INVESTMENT & FUNDING SCENARIO 105
FIGURE 35 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT 227
FIGURE 36 NIH FUNDING, 2014–2024 231
FIGURE 37 EUROPE: GENE THERAPY MARKET SNAPSHOT 241
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION) 354
FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 355
FIGURE 40 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 358
FIGURE 41 GENE THERAPY MARKET: COMPANY FOOTPRINT 359
FIGURE 42 GENE THERAPY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 365
FIGURE 43 EV/EBITDA OF KEY VENDORS 368
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 368
FIGURE 45 GENE THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 369
FIGURE 46 BIOGEN: COMPANY SNAPSHOT (2023) 375
FIGURE 47 NOVARTIS: COMPANY SNAPSHOT (2023) 379
FIGURE 48 ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 383
FIGURE 49 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023) 387
FIGURE 50 JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT (2023) 391
FIGURE 51 FERRING: COMPANY SNAPSHOT (2023) 393
FIGURE 52 PFIZER: COMPANY SNAPSHOT (2023) 397
FIGURE 53 AMGEN: COMPANY SNAPSHOT (2023) 399
FIGURE 54 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT (2023) 402
FIGURE 55 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2023) 405
FIGURE 56 BIOMARIN PHARMACEUTICAL: COMPANY SNAPSHOT (2023) 406
FIGURE 57 KYOWA KIRIN: COMPANY SNAPSHOT (2023) 410
FIGURE 58 NIPPON SHINYAKU: COMPANY SNAPSHOT (2023) 413
FIGURE 59 PTC THERAPEUTICS: COMPANY SNAPSHOT (2023) 415
FIGURE 60 UNIQURE: COMPANY SNAPSHOT (2023) 417
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11